11 August 2021 - Deborah Wilkes
Premium
New Zealand's Medicines Classification Committee (MCC) has deferred a decision on an application to change the status of allopurinol for preventing gout, but has made recommendations on proposals involving choline salicylate, hyaluronidase and ibuprofen.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.